A secondary analysis from the Women's Health Initiative has found that past use of hormone therapy with estrogen plus progestin increases the risk of dying from non–small cell lung cancer for women who develop the disease.
The findings, presented at the 45th Annual Meeting of the American Society of Clinical Oncology in Orlando, Fla, add to growing concerns about the safety of hormone therapy in some women. “These data, together with recent results indicating higher breast cancer risk, suggest cancer impact should influence risk-to-benefit consideration for combined hormone therapy use,” the authors noted.
Hampton T. Lung Cancer Mortality Higher in Women Who Used Combination Hormone Therapy. JAMA. 2009;302(6):615–616. doi:10.1001/jama.2009.1117
Customize your JAMA Network experience by selecting one or more topics from the list below.